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Abstract 
Mantle cell lymphoma (MCL) is a B-cell neoplasm 
that usually carries the t(11;14)(q13;q32) 
translocation and constitutively overexpresses cyclin 
D1. The clinical evolution is relatively aggressive 
with a poor response to conventional therapeutic 
regimens, frequent relapses and a median overall 
survival of 3-5 years. MCL has a wide spectrum of 
growth patterns. Most cases have a vaguely nodular 
and/or diffuse growth pattern, very rare cases have a 
follicular growth pattern, and a larger minority has a 
mantle zone growth pattern in which the lymphoma 
grows as an expanded ring around reactive germinal 
centers. "In situ MCL" is considered as a very early 
stage of MCL or even a pre-neoplastic state, and 
thought to be the tissue equivalent of clonal 
circulating cells carrying the genetic alterations 
found in their overt counterpart lymphomas. The 
impact of some of the newer therapeutic approaches 
remains to be established. 
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Clinics and pathology 
Disease 
Mantle cell lymphoma (MCL) is a B-cell neoplasm 
generally composed of monomorphic small to 
medium-sized lymphoid cells with irregular nulear 
contours and a CCND1 translocation   (Swerdlow, et 
al ,2008. Swerdlow, et al, 2016). 
'In situ MCL' is considered as a very early stage of 
MCL or even a pre-neoplastic state, and thought to 
be the tissue equivalent of clonal circulating cells 
carrying the genetic alterations found in their overt 
counterpart lymphomas. These are mainly incidental 
findings, and are defined as lesions that remain 
compartmentalized (germinal centre/mantle zone) 
without altering the normal/reactive lymph node 
(LN) architecture. (Hsu, et al. 2014. Cortelazzo, et 
al. 2012). 
Phenotype/cell stem origin 
The postulated normal counterpart of MCL is 
peripheral B-cell of inner mantle zone, mostly of 
naïve pre-germinal center type (Swerdlow, et al, 
2008). 
MCL expresses CD20, PAX5, CD43, bcl2, and 
usually positive for CD5, cyclinD1, but there are 
minority of cases are negative for CD5, cyclinD1. 
Sox11 can express in cyclinD1 negative cases. Rare 
MCL are negative for cyclin D1 and the t(11;14) but 
have an expression profile and other features 
indistinguishable from conventional MCL, which 
have a high expression of cyclinD2 or cyclinD3. 
MCL is negative for CD10 and bcl6 (Swerdlow, et 
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al, 2008. Swerdlow, et al, 2016). Aberrant 
phenotypes have been described, sometimes in 
association with blastoid/pleomorphic variants; 
these variants include negativity for CD5 (12% of 
cases), and positivity for CD10 (8%), CD23 (21%), 
bcl-6 (12%), and MUM1 (35%). (Cortelazzo, et al. 
2012). 
Epidemiology 
The incidence of MCL is about 3-10% of non-
Hodgkin lymphoma. It occurs in middle-aged to 
older individuals with a median age about 60 and a 
variably marked male predominance (about 2:1 or 
greater) (Swerdlow, et al, 2008. Swerdlow, et al, 
2016).  
 
Bermudez et al studied a series of 341 consecutive 
lymph node resection specimens from patients 
diagnosed with colorectal and breast 
adenocarcinoma and incidental and isolated MCLIS 
was found in 2/341 patients(0.59%).( Bermudez, 
2016). 
Clinics 
Lymph nodes are the most commonly involved site; 
the spleen and bone marrow, with or without 
peripheral blood (PB) involvement, are other 
important sites of disease. Other extranodal sites are 
frequently involved, including the gastrointestinal 
tract and Waldeyer ring. Most cases of multiple 
lymphomatous polyposis represent MCL 
(Swerdlow, et al, 2008. Swerdlow, et al, 2016). 
 
Leukemic phase of mantle cell lymphoma. 
Peripheral blood. Small to medium sized lymphoid 
cells with slightly to markedly irregular nuclear 
contour. The nuclei have moderately dispersed 
chromatin bur inconspicuous nucleoli. From a 
patient with 46,XX,t(11;14)(q13;q32) - Text and 
iconography Courtesy Georges Flandrin 2005. 
Pathology 
Morphologically, classical MCL is a monomorphic 
lymphoid proliferation with a vaguely nodular 
(13%), diffuse (61%), mantle zone (26%) or rarely 
follicular growth pattern. Most cases are composed 
of small to medium-sized lymphoid cells with 
slightly to markedly irregular nuclear contours, most 
closely resembling centrocytes. The nuclei have at 
least somewhat dispersed chromatin but conspicuous 
nucleoli. Hyalinized small vessels and scattered 
single epithelioid histiocytes are commonly seen. 
Evaluation of the proliferation fraction either by 
counting mitotic figures or estimating the proportion 
of Ki67 positive nuclei is important for prognosis. 
The proliferation activity may vary in different 
cases, but it is generally low, with a percentage of 
Ki-67 positive cells around 15-30%. In blastoid 
variant there is a high proliferative activity (Ki-67 
positive cells > 40%) (Swerdlow, et al, 2008. 
Swerdlow, et al, 2016. Cortelazzo, et al. 2012).  
 
There are some variants of MCL: blastoid and 
pleomorphic variant (aggressive), and small cell, 
marginal zone-like variant.  
 
 Blastoid variant:   loss of a mantle zone growth 
pattern, increase in nuclear size and mitotic activity, 
cells resemble lymphoblasts with dispersed 
chromatin and a high mitotic rate (usually at least 20-
30/10HPF). 
 Pleomorphic variant:  cells are pleomorphic but 
many are large with oval to irregular nuclear 
contours, generally pale cytoplasm and often 
prominent nucleoli in at least some of the cells. 
 Small cell variant:   small round lymphocytes with 
more clumped chromatin, either admixed or 
predominant, mimicking a small lymphocytic 
lymphoma. 
 Marginal zone-like variant:   prominent foci of 
cells with abundant pale cytoplasm resembling 
marginal zone of monocytoid B-cell mimicking a 
marginal zone lymphoma; sometimes these paler 
foci may also resemble proliferation centers of 
chronic lymphocytic leukaemia/small lymphocytic 
lymphoma. 
 'In situ' MCL shows involvement almost 
exclusively restricted to the inner mantle zones or to 
narrow mantles, consisting of cyclin D1+ cells 
typically in the inner mantle zones of follicles in the 
absence of overt lymphoma. The mantle zones 
appear normal or only mildly expanded. In many 
cases, this is an incidental finding, though can be 
found in the presence of other small B cell 
lymphomas or overt MCL. In 2016 WHO 
classification, 'in situ MCL' is renamed as in situ 
mantle cell neoplasia (ISMN) to distinguish it from 
overt MCL, and can be considered observation in 
patients with indolent disease (asymptomatic with 
low Ki67 or leukemic non-nodal disease) (Lynch, et 
al. 2017). These cases must be distinguished from 
mantle cell lymphoma with a mantle zone pattern 
and overt mantle cell lymphoma because they may 
not require therapeutic intervention Carvajal-
Cuenca, 2012).  
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Two subtypes of MCL based on different clinic-
pathological features and molecular abnormalities 
are recognized: classical MCL and leukemic non-
nodal MCL.  
 
 'leukemic' non-nodal MCL  (previously mistaken 
for CLL) is a distinct variant which is associated with 
hyper-mutated IGHV, no expression of SOX11, low 
Ki67, and few or no other molecular abnormalities 
beyond a t(11;14) translocation. It typically has an 
indolent clinical course, infrequent peripheral 
lymphadenopathy, but is commonly associated with 
splenomegaly, bone marrow, and peripheral blood 
involvement (limited to blood and bone marrow) 
(Lynch, et al. 2017. Ondrejka, et al, 2011).
 
 
Figure1. Mantle cell lymphoma. Diffuse architectural effacement can be seen, composed of small to medium-
sized lymphoid cells. (HE staining). 
 
Figure 2. Mantle cell lymphoma, blastoid variant. The lymphoid cells are medium in size, resembling 
lymphoblasts with dispersed chromatin and a high mitotic rate. (HE staining). 
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Figure 3. The cells are positive for CD20. 
 
Figure 4. The cells are positive for CD5. 
 
Figure 5. The cells are positive for cyclinD1. 
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Figure 6A. Mantle cell lymphoma, 'in situ'. Morphology reveals a lymph node with multiple reactive-appearing 
follicles and prominent paracortical hyperplasia (HE staining). 
 
Figure 6B. Higher power view of one reactive-appearing follicles with germinal centers and normal mantle 
zones (HE staining). 
 
Figure 6C. The mantle zone cells are positive for CD20. 
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Figure 6D. The cells are positive for CD5 with numerous T-cells in paracortical regions. 
 
Figure 6E. The cells are positive for cyclin D1 highlighting scattered positive cells in mantle zones. 
 
Figure 6F. The proliferation index of Ki67 is low in mantle zone cells. 
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Treatment 
MCL has a median survival of 3-5 years with a short 
remission duration to standard therapies, but the vast 
majority of patients cannot be cured. The impact of 
some of the newer therapeutic approaches remains to 
be established. (Swerdlow, et al, 2008. Swerdlow, et 
al, 2016). For selected indolent (either low tumor 
burden/low proliferative index nodal form or 
leukemic non-nodal form are often asymptomatic 
and can be observed with favorable long-term 
outcomes), low MIPI MCL patients, initial 
observation may be appropriate therapy. For 
younger patients with intermediate or high risk MIPI 
MCL, aggressive therapy with a cytarabine 
containing regimen autologous stem cell 
transplantation should be considered. For older MCL 
patients with intermediate or high risk MIPI, 
combination chemotherapy with R-CHOP, R-
Bendamustine, or a clinical trial should be 
considered. At the time of relapse, agents directed at 
activated pathways in MCL cells such as bortezomib 
(NFkB inhibitor), BTK inhibitors or CAL-101 (B-
cell receptor inhibitors) or lenalidamide (anti-
angiogenesis) have clinical activity in MCL patients. 
Autologous or allogeneic stem cell transplantation 
can also be considered in young patients. (Vose, 
2012. Vose, 2015. Vose, 2017).  
 
It is important to recognize that ISMN does not 
represent a lymphoma diagnosis and no additional 
evaluation or therapy is warranted. (Lynch, et al. 
2017)  
 
MCL is heterogeneous a disease, and so are the 
people that have it; although guidelines are 
appropriate, therapeutic approaches must be 
individualized based on a variety of factors and need 
for personalized therapy to ensure optimal 
outcomes..(Martin, et al. 2017. Sandoval-Sus, et 
al.2017). Targeted strategies include the proteasome 
inhibitors, immune modulatory drugs (IMiDs), 
mammalian target of rapamycin (mTOR) inhibitors 
and especially inhibitors of the B-cell receptor 
pathway (Dreyling, 2015). Given the excellent OS 
rates regardless of initial therapy in patients with 
early-stage MCL, de-intensified therapy to limit 
treatment-related toxicity is a reasonable approach 
(Dabaja, 2017). 
Prognosis 
The most consistently reported adverse 
histopathological prognostic parameter is a high 
mitotic rate. A high proliferation index of Ki67 is an 
adverse prognostic indicator. Some studies reported 
adverse prognostic features includes: 
blstoid/pleomorphic morphology, trisomy 12, 
karyotypic complexity, TP53 
mutation/overexpression/loss and overt PB 
involvement, gains of chromosome 3q and deletions 
of 9q. The small cell variant and 'in situ' MCL appear 
to have better course.  (Swerdlow, et al, 2008. 
Swerdlow, et al, 2016). The absence of SOX-11 or a 
low Ki-67 may correlate with a more indolent form 
of MCL. The MCL international prognostic index 
(MIPI) is the prognostic model most often used and 
incorporates ECOG performance status, age, 
leukocyte count, and lactic dehydrogenase. A 
modification of the MIPI also adds the Ki-67 
proliferative index if available (Vose, 2012. Vose, 
2015. Vose, 2017). The use of intensive frontline 
therapies including rituximab and consolidated by 
ASCT ameliorates response rate and prolongs 
progression-free survival, but any impact on survival 
remains to be proven. The development of targeted 
therapies as the consequence of better dissection of 
pathogenetic pathways in MCL might improve the 
outcome of conventional chemotherapy in most 
patients and spare the toxicity of intense therapy in a 
minority of MCL patients characterized by a 
relatively indolent disease (Cortelazzo, et al. 2012).  
 
The 'in situ MCL' is associated with incidental 
finding, indolent clinical course and lower tumor 
burden. .(Hsu, et al. 2014) 
Genetics 
Immunoglobulin genes are rearranged. Variable 
region genes are unmutated in the majority of the 
cases, but in 15-40% of the cases, IG genes show 
somatic hypermutation. The t(11;14)(q13;q32) 
between IGH and cyclinD1 (CCND1) genes is 
present in almost all cases and considered the 
primary genetic event. Inactivating mutations of the 
ATM gene at 11q22-23 have been detected in 40-
75% of MCL. (Swerdlow, et al, 2008. Swerdlow, et 
al, 2016). MCL represents the lymphoma subtype 
with the highest number of cytogenetic alterations. 
Secondary chromosomal aberrations including gains 
in 3q26(31-50%), 7p21 (16-34%) and 8q24 (16-
36%: MYC) as well as losses of 1p 13-p31 (29-
52%), 6q23-27 (23-38%), 9p21 (18-31%), 11q22-23 
(21-59%), 13q11-q13 (22-55%), 13q14-q34 (43-
51%) and 17p13pter (21-45%) has been reported. 
Trisomy 12 was found in 25% of cases. (Cortelazzo, 
et al. 2012).  One study identified a functional LINC-
ROR (lncRNA ROR-AS1) involved with regulation 
of gene transcription via associating with PRC2 
complex, and may serve as a novel biomarker in 
MCL patients. (Hu, et al.2017) There is also 
improved understanding of the molecular 
abnormalities seen in MCL, with alterations in 
ATM, cyclin D1, NOTCH1, and NOTCH2 being 
more common. (Lynch, et al. 2017).  
 
The t(11;14) was demonstrated in nine of nine cases 
with an 'in situ MCL' pattern of cyclin D1-positive 
cells by conventional cytogenetics of lymph node or 
peripheral blood samples (3 cases) and/or by FISH 
studies (8 cases) (Carvajal-Cuenca, 2012). 
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Cytogenetics 
Cytogenetics morphological 
t(11;14)(q13;q32) IGH/CCND1 
Genes involved and 
proteins 
CCND1 
Location 
11q13.3 
DNA/RNA 
5 exons. 
Protein 
CCND1 binds and activates the G1 cyclin dependent 
kinases, CDK4 and CDK6. CDK-cyclin D complex 
phosphorylates members of the retinoblastoma 
protein family. Regulates the G1/S transition in the 
cell cycle. Essential for G1 progression. Promotes 
cellular proliferation and block cell differentiation. 
Found involved in translocations with fusion genes, 
amplified and over-expressed, or mutated in a 
number of cancers. 
IGH 
Location 
14q32.33 
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